Tecentriq Combo A New Weapon As China Tackles HCC
Large Local Cohort In IMbrave150
Executive Summary
With the country accounting for 50% of global liver cancer cases, China aims the crosshairs with the help of novel therapies.
You may also be interested in...
China CSCO Hails Rising Liver Cancer Innovation Ready To Take On World
The Chinese Society of Clinical Oncology (CSCO) annual meeting, against the background of the global pandemic, has one clear message that local researchers and players are pressing ahead to take a leadership role in cutting-edge cancer research globally.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.